This research aims to understand what truly matters to patients like yourself when making decisions about, and undergoing treatment with advanced therapies for Crohn's and Colitis.
Advanced therapies include biological drugs, such as infliximab, adalimumab, ustekinumab, vedolizumab, and golimumab. It also includes small molecule drugs, including tofacitinib, upadacitinib and ozanimod.
By participating in this study, you have a valuable opportunity to share your experiences and priorities related to your treatment.
The purpose of this research project is to explore the priorities, preferences, and experiences of patients with Crohn’s disease or Ulcerative Colitis or Indeterminate Colitis regarding treatment with advanced therapies. These drugs can be given in different ways, at different doses, and have different side effects. They also need different types of monitoring. But we don’t know much about what patients care about most when taking these therapies.
Through one-to-one interviews, researchers aim to understand patients’ viewpoints better. This will help ensure care is focused on what matters to patients. The hope is that this research will give patients a voice and improve shared decision making about IBD treatment.
The study involves just one 60-minute interview, which will be be held virtually or over the telephone. A researcher will ask you questions about your experiences with and opinions on advanced IBD therapy.
To take part in this study, you must be:
- diagnosed with Crohn’s disease, Ulcerative Colitis or Indeterminate Colitis
- aged 18 years or older
- currently receiving biologic therapy or small molecules
- able to communicate in English.
- UK-based
If you're not sure whether you are currently receiving biologic therapy or small molecules, please get in touch with the researcher at rh420@student.le.ac.uk.
If you are interested in taking part, or would like more information about the study, please complete the form below:
By entering your details, you are not committing to take part, but you will be redirected automatically to the study webpage. Taking part is completely voluntary and you can withdraw at any time.